scholarly journals Interferon-gamma release assay testing to assess COVID-19 vaccination response in a SARS-CoV-2 seronegative patient on rituximab: a case report

2021 ◽  
Author(s):  
Jessica Ferguson ◽  
Kanagavel Murugesan ◽  
Niaz Banaei ◽  
Anne Liu
Keyword(s):  
Case Report ◽  
Interferon Gamma ◽  
Interferon Gamma Release Assay ◽  
Vaccination Response ◽  
Seronegative Patient ◽  
Release Assay

scholarly journals Use of QuantiFERON-TB Gold to determine the aetiology of idiopathic erythema induratum: A case report

2018 ◽  
Vol 6 ◽  
pp. 2050313X1880407
Author(s):  
Alisa Brandon ◽  
Asfandyar Mufti ◽  
R. Garry Sibbald
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Case Report ◽  
Hypersensitivity Reaction ◽  
Interferon Gamma ◽  
Vitamin B6 ◽  
Tuberculosis Infection ◽  
Interferon Gamma Release Assay ◽  
Release Assay ◽  
Lobular Panniculitis

Although rare, erythema induratum is the most common entity presenting as lobular panniculitis with vasculitis. It is usually caused by a hypersensitivity reaction to Mycobacterium tuberculosis, although other aetiologies have been reported. We present a case of a 73-year-old male with multiple recurring tender erythematous nodules on the backs of both calves and shins. Prior to arrival in our clinic, the patient underwent a 9-month course of isoniazid with no improvement and subsequently received a diagnosis of idiopathic erythema induratum. We performed an interferon-gamma release assay QuantiFERON-TB Gold which was positive for M. tuberculosis infection. The patient was successfully treated with ethambutol 1.6 g for 1 month; pyrazinamide 2 g for 2 months; and isoniazid 300 mg, vitamin B6 25 mg, and rifampin 600 mg for 6 months. This case highlights the utility of using interferon-gamma release assay QuantiFERON-TB Gold and a multidrug regiment over isoniazid in erythema induratum.

scholarly journals Role of interferon gamma release assay in the diagnosis and management of Mycobacterium tuberculosis-associated uveitis: a review

2021 ◽  
Vol 6 (1) ◽  
pp. e000663
Author(s):  
Samra Rahman ◽  
Muhammad Irfan ◽  
M A Rehman Siddiqui
Keyword(s):  
Interferon Gamma ◽  
Interferon Gamma Release Assay ◽  
Limited Evidence ◽  
Ocular Tuberculosis ◽  
Diagnosis And Management ◽  
Pubmed Database ◽  
Interferon Gamma Release Assays ◽  
Infectious Uveitis ◽  
Release Assay

Tuberculosis (TB)-associated uveitis is a common cause of infectious uveitis in the developing world. Diagnosis of TB uveitis remains a challenge. The role of interferon gamma release assays (IGRAs) is uncertain. Herein we summarise the available literature on the utility of IGRAs in the diagnosis and management of TB uveitis. We searched PubMed database from 1 August 2010 to 31 July 2020 using the following keywords alone and in combination: ‘interferon-gamma release assay’, ‘QuantiFERON’, ‘T-SPOT.TB’, ‘TB uveitis’, ‘serpiginous like choroiditis’, ‘tuberculoma’, ‘TB vasculitis’, ‘TB panuveitis’ and ‘ocular tuberculosis’. Data from 58 relevant studies were collated. The review is focused on currently marketed versions of IGRA tests: QuantiFERON-TB Gold In-Tube assay, QuantiFERON-TB Gold Plus assay (QFT-Plus) and T-SPOT.TB. We found limited evidence regarding the diagnostic utility of IGRA in patients with uveitis. No study was identified evaluating the newer QFT test—the QFT-Plus—in patients with uveitis. Similarly, there is lack of data directly comparing QFT-Plus with T-SPOT.TB specifically for the diagnosis of TB uveitis.

Esophageal Tuberculosis in a Patient on Maintenance Dialysis: Advantages of Interferon-Gamma Release Assay

Renal Failure ◽  
2009 ◽  
Vol 31 (3) ◽  
pp. 248-250 ◽  
Author(s):  
Olesia Damaschin ◽  
Omar Dahmani ◽  
Frédéric Faibis ◽  
Marie-Claude Demachy ◽  
Mahdi Abtahi ◽  
...  
Keyword(s):  
Interferon Gamma ◽  
Interferon Gamma Release Assay ◽  
Esophageal Tuberculosis ◽  
Release Assay ◽  
Maintenance Dialysis
Sign in / Sign up

Export Citation Format

Share Document